Human Body Burden of Pseudomonas aeruginosa, Antibiotics Susceptibility Pattern and Presence of Extended Spectrum β-lactamase and Carbapenemase encoding Genes in Lagos State, Nigeria

• Published in: Journal of Applied Sciences and Environmental Management 2022-12, Vol.26 (12), p.1937-1941
• Main Authors: Egwuatu, T. O. G., Osuagwu, C. S., Olorunnimbe, O. R., Ogunrinde, O. G., Osibeluwo, B. B.
• Format: Article
• Language: English
• Subjects: Antibiotics resistance; Carbapenem resistance; Extended Spectrum Beta Lactamase; Pseudomonas aeruginosa
• ISSN: 1119-8362; 2659-1502; 2659-1502; 2659-1499
• DOI: 10.4314/jasem.v26i12.7

Pseudomonas aeruginosa, frequently associated with a wide range of community and nosocomial infections, is notorious for being resistant to several classes of antibiotics with only a handful of antibiotics still effective. This study determined the human body burden of P. aeruginosa as well as antibiotics susceptibility pattern and presence of extended spectrum beta-lactamase (ESBL) and carbapenemase encoding genes in Lagos state, Nigeria using standard methods. Out of 103 bacterial cultures collected, 31 P. aeruginosa isolates were obtained, mostly originating from wound and urine samples. High rates of antibiotics resistance were observed to fluoroquinolone and cephalosporins with 24 (77.4%) resistant to ciprofloxacin, 19 (61.3) to cefotaxime, and 18 (58.1%) to ceftriaxone as well as amoxicillin clavulanic acid. However, resistance to ceftazidime and meropenem were low with only 6 (19.4%) and 5 (16.1%) resistant isolates respectively. ESBL production was detected in 10 (32.3%) of the isolates with ESBL genes detected in 6 (60%) of the 10 isolates. Ceftazidime and meropenem are viable therapeutic options for P. aeruginosa infections. Selection and dissemination of ESBL producing P. aeruginosa must be curtailed to prevent the loss of efficacy in currently available viable therapeutic options.